RecallHawk

TRIUMEQ (ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE)

VIIV HLTHCARE

Summary

FDA approved TRIUMEQ (ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE) by VIIV HLTHCARE. NDA (New Drug) approval (Labeling) on 2025-10-28. TABLET, ORAL.

Details

Source

Drug Approval

External ID

NDA205551-34

Action Date

2025-10-28

Status

Approved

Category

drug

Product Code

NDA (New Drug)

Product Description

TRIUMEQ (generic: ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE), TABLET, ORAL. Application: NDA205551

Context & Analysis

VIIV HLTHCARE has 6 FDA actions in our database.

Frequently Asked Questions

How often does VIIV HLTHCARE have FDA actions?

VIIV HLTHCARE has 6 FDA actions in our database, including 0 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "NDA205551-34" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions